Clinical Research Career Development Program

描述（由申请人提供）：我们要求为达纳法伯/哈佛癌症中心（DF/HCC）的高级研究员和初级教师更新我们的多学科转化肿瘤学研究K-12培训计划。该项目于2002年首次资助，支持了来自不同亚专业背景（外科、医学、放射肿瘤学）和不同研究兴趣的14名研究员，以及由CURE Supplements资助的两名少数族裔研究员。它的目标是培养下一代在实验室科学、人口科学和临床医学之间工作的临床研究人员。它强调分子肿瘤学的研究训练及其在临床医学中的应用。每个受训者由两位导师指导，一位负责实验室或流行病学调查，另一位负责临床调查。在最初的两年里，受训者将继续他们工作的临床前部分，并获得临床研究的教学背景，这是他们工作的第二个2 - 3年阶段所必需的，这强调了转化部分的发展和开始。每个阶段的准确时间和内容取决于获奖者先前的培训和项目的性质。受培训者在他们的任期内作为DF/HCC疾病项目的成员参与。学者们在临床研究的方法、伦理和监管方面进行研究生培训。如果学生尚未获得高等学位，我们要求他们获得高等学位。许多学者以实验室科学博士学位进入该项目；他们的训练强调临床调查的准备和负责任的研究行为，即使他们追求进一步的实验室工作。另一些人主要来自临床背景，需要在实验室或流行病学方法方面进行强化的实践培训，以提高他们对癌症生物学的理解。我们K-12项目的所有11名毕业生目前都在DF/HCC研究机构或其他大学担任教职，所有5名现任学者也是如此。所有毕业生都拥有独立的同行评审基金。导师从哈佛医学院（HMS）和DF/HCC的高级教师永久名单中选择。麻省理工学院David Koch综合癌症研究中心的教师也担任了导师，其主任Tyler Jacks是我们咨询委员会的成员。根据需要，其他导师会被添加到这个列表中。哈佛医学院（HMS）、哈佛公共卫生学院（HSPH）和DF/HCC联合医院的实验室可以接待K-12学者。学者可以使用广泛的临床试验系统（有500个活跃试验）和DF/HCC的19个核心设施，以及医院的研究核心和设施。候选人是从完成肿瘤专业临床培训的医生中挑选出来的，并且至少有两年的进一步基础或临床研究经验。获奖者包括内科、放射学和外科肿瘤学家，尽管由于对药物开发的重视，内科肿瘤学家占主导地位。K-12获奖者是通过竞争激烈的DF/ hc范围内的征集选出的，并特别鼓励妇女和少数民族候选人。我们的11名毕业生中有5名是女性，两名K-12学者获得了NCI的CURE补充资助。咨询委员会由16名成员组成，其中包括5名妇女和两名少数民族研究人员，他们在临床和实验室研究以及学术生涯发展方面有不同的兴趣，从申请人中挑选学员。同一咨询委员会每半年审查候选人的进展，包括实验室和临床导师的报告，并建议改变导师，研究项目或实习生状态（从项目毕业）。咨询委员会寻求培训项目主管和机构办公室对少数民族和妇女职业发展的投入，以增加我们申请者的多样性。在上一次拨款更新期间任命的六名新学者中，有两名是少数族裔科学家，这些科学家是由CURE少数族裔补充计划资助的。一项少数族裔同胞指导计划预计将在未来的资助期内增加少数族裔的申请。基于过去受训者的显著出版记录和学术进步，以及K-12资助名额的强大且不断增长的优秀候选人池，我们申请五个名额来续签这项资助。

DESCRIPTION (provided by applicant): We request renewal of our multidisciplinary K-12 training program in translational oncology research for senior fellows and junior faculty of the Dana Farber/Harvard Cancer Center (DF/HCC). This program was first funded in 2002 and has supported 14 fellows from diverse subspecialty backgrounds (surgery, medicine, radiation oncology) and with diverse research interests, as well as two Minority Fellows funded by CURE Supplements. . Its objective is to produce a next generation of clinical investigators who work at the interface between laboratory science, population science, and clinical medicine. It emphasizes research training in molecular oncology and its application to clinical medicine. Each trainee is guided by two mentors, one for their laboratory or epidemiologic investigation, and a second mentor for their clinical investigation. Trainees spend the initial two years of service on the grant pursuing the preclinical component of their work and acquiring the didactic background in clinical investigation necessary for the second two-three year phase of their work, which emphasizes the development and initiation of the translational component. The precise timing and content of each phase depends upon the prior training of the awardee and the nature of the project. Trainees participate as members of DF/HCC disease programs throughout their tenure on this grant. Scholars pursue postgraduate training in the methods, and in the ethical, and regulatory aspects of clinical research. We require scholars to obtain an advanced degree if one has not already been obtained. Many scholars enter the program with PhD degrees in laboratory sciences; their training emphasizes preparation for clinical investigation and the responsible conduct of research even as they pursue further laboratory work. Others come from a predominantly clinical background and require intensive hands-on training in laboratory or in epidemiological methods and to enhance their understanding of cancer biology.. All eleven graduates of our K-12 program currently occupy faculty positions in DF/HCC research facilities or in other universities, as do all five of the current scholars. All graduates hold independent peer reviewed funding. Mentors are selected from a permanent list of senior faculty of Harvard Medical School (HMS) and the DF/HCC. Faculty at the David Koch Center for Integrative Cancer Research at the Massachusetts Institute of Technology have also served as mentors, and its Director, Tyler Jacks, participates as a member of our Advisory committee. Additional mentors are added to this list as needed. The laboratories of the Harvard Medical School (HMS), the Harvard School of Public Health (HSPH), and the DF/HCC consortium hospitals may host K-12 scholars. Scholar have access to the extensive clinical trials system (with 500 active trials) and the 19 core facilities of the DF/HCC, and to hospital research cores and facilities.. Candidates are drawn from the pool of physicians who have completed clinical training in an oncological specialty, and have at least two years of further basic or clinic research experience. Awardees include medical, radiation, and surgical oncologists, although, because of the emphasis on drug development, medical oncologists have predominated. K-12 awardees are selected through a highly competitive DF/HCC-wide solicitation as slots become available, with specific encouragement of women and minority candidates. Five of our eleven graduates have been women, and two K-12 scholars have been funded with CURE Supplements from NCI. An advisory committee, composed of 16 members, including 5 women and two minority investigators, with diverse interests in clinical and laboratory research and in academic career development, selects trainees from the applicant pool. The same advisory committee reviews the progress of the candidates, including reports from both laboratory and clinical mentors, on a semiannual basis, and recommends changes in mentorship, research program, or trainee status (graduation from the program). The advisory committee seeks the input of training program directors and institutional offices for minority and women's career development in order to increase the diversity of our applicant pool. Two of the six new scholars appointed during the last grant renewal were minority scientists supported through CURE Minority Supplements to the K- 12. A minority fellow mentoring program is expected to increase minority applications in future grant periods. Based upon the notable track record of publications and academic progress of past trainees, and the strong and growing pool of exceptional candidates for slots on the K-12 grant, we request five slots for the renewal of this grant.